본문 바로가기
KERD
논문KCI 등재

백출의 파골세포 분화에 미치는 영향

Effect of Atractylodis Rhizoma Alba on Osteoclast Formation

이명수|박기인|오재민|전병훈|박성태
한의병리학회 (The Society of Pathology in Korean Medicine)|2011.02|동의생리병리학회지 (Journal of Physiology & Pathology in Korean Medicine)|제25권 제1호|pp. 109-114

2

조회

0

다운로드

8

인용

0

참고문헌

키워드

OsteoporosisOsteoclastAtractylodis Rhizoma Alba
주제분류한의학

초록

Atractylodis Rhizoma Alba is commonly used herbal medicine and it has been known that has immuno-regualtory effects and anti-cancer effects. The inhibition of osteoclastogenesis is essential for the prevention and treatment of osteoporosis. The aim of this study was to evaluate the effects of Atractylodis Rhizoma Alba on osteoclast differentiation in vitro and on resorbing activity of osteoclast. Osteoclast formation was evaluated in bone marrow cells (BMC) in the presence or absence of Atractylodis Rhizoma Alba. The expression of c-fos, tartrate-resistant acid phosphatase (TRAP), OSCAR, DC-STAMP, cathepsin K, MafB and NFATc1 mRNA in osteoclast precursor were assessed by RT-PCR. The levels of TNF receptor-associated factor-6 (TRAF-6), c-fos and NFATc1 protein were assessed by Western blot analysis. Also the correlation with MAPKs and NF-kB pathways were measured by using Western blot analysis. With bone resorption study, I tried to evaluate the inhibitory effects of Atractylodis Rhizoma Alba on mature osteoclast function. Atractylodis Rhizoma Alba inhibited the RANKL induced osteoclastic differentiation from bone marrow macrophage in a dose dependant manner without cellular toxicity. Gene expression of c-fos and NFATc1 was significantly down regulated with Atractylodis Rhizoma Alba treatment. Atractylodis Rhizoma Alba markedly inhibited the RANKL-induced osteoclastogenesis through suppression of nuclear factor kappa b (NF-κB) pathway, down stream pathway of p38, ERK and JNK pathway. Taken together, I concluded that Atractylodis Rhizoma Alba have beneficial effect on osteoporosis by inhibition of osteoclast differentiation and by inhibition of functioning osteoclast. Thus I expect that Atractylodis Rhizoma Alba could be a treatment option for osteoporosis.

Abstract

Atractylodis Rhizoma Alba is commonly used herbal medicine and it has been known that has immuno-regualtory effects and anti-cancer effects. The inhibition of osteoclastogenesis is essential for the prevention and treatment of osteoporosis. The aim of this study was to evaluate the effects of Atractylodis Rhizoma Alba on osteoclast differentiation in vitro and on resorbing activity of osteoclast. Osteoclast formation was evaluated in bone marrow cells (BMC) in the presence or absence of Atractylodis Rhizoma Alba. The expression of c-fos, tartrate-resistant acid phosphatase (TRAP), OSCAR, DC-STAMP, cathepsin K, MafB and NFATc1 mRNA in osteoclast precursor were assessed by RT-PCR. The levels of TNF receptor-associated factor-6 (TRAF-6), c-fos and NFATc1 protein were assessed by Western blot analysis. Also the correlation with MAPKs and NF-kB pathways were measured by using Western blot analysis. With bone resorption study, I tried to evaluate the inhibitory effects of Atractylodis Rhizoma Alba on mature osteoclast function. Atractylodis Rhizoma Alba inhibited the RANKL induced osteoclastic differentiation from bone marrow macrophage in a dose dependant manner without cellular toxicity. Gene expression of c-fos and NFATc1 was significantly down regulated with Atractylodis Rhizoma Alba treatment. Atractylodis Rhizoma Alba markedly inhibited the RANKL-induced osteoclastogenesis through suppression of nuclear factor kappa b (NF-κB) pathway, down stream pathway of p38, ERK and JNK pathway. Taken together, I concluded that Atractylodis Rhizoma Alba have beneficial effect on osteoporosis by inhibition of osteoclast differentiation and by inhibition of functioning osteoclast. Thus I expect that Atractylodis Rhizoma Alba could be a treatment option for osteoporosis.

참고문헌 (19)

  1. Cooper, C, "population-based study of survival after osteoporotic fractures", Am J Epidemiol, 137(9), pp.1001~1005 (1993)
  2. Klotzbuecher, C.M, "Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis", Bone Miner Res, 15(4), pp.721~739 (2000)
  3. Goltzman, D, "Discoveries, drugs and skeletal disorders", Nat Rev Drug Discov, 10, pp.784~796 (2002)
  4. Rodan, G.A, "approaches to bone diseases", Science, 289(5484), pp.1508~1514 (2000)
  5. Nishikawa, M, "Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures", Bone, 18, pp.9~14 (1996)
  6. Kwak, H.B, "Risedronate Directly Inhibits Osteoclast Differentiation and Inflammatory Bone Loss", BIOLOGICAL & PHARMACEUTICAL BULLETIN, 32(7), pp.1193~1198 (2009), PHARMACEUTICAL SOC JAPAN
  7. Solomon, D.H., "Osteoporosis treatments and adverse events", Curr Opin Rheumatol, 21(4), pp.363~368 (2009)
  8. 곽한복, "녹용 물 추출물의 파골세포 분화 억제효과", 동의생리병리학회지, 22(4), pp.891~895 (2008), 대한동의병리학회
  9. 리연, "오미자 물 추출물이 파골세포 분화에 미치는 영향", 동의생리병리학회지, 24(5), pp.848~853 (2010), 대한동의병리학회
  10. Eum, H.A., "Anti-inflammatory activity of CML-1: An herbal formulation", AMERICAN JOURNAL OF CHINESE MEDICINE, 33(1), pp.29~40 (2005), WORLD SCIENTIFIC PUBL CO PTE LTD
  11. Kamei, T., "The effect of a traditional Chinese prescription for a case of lung carcinoma", J Altern Complement Med, 6(6), pp.557~559 (2000)
  12. Takayanagi, H, "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts", Dev. Cell, 3, pp.889~901 (2002)
  13. Yarom, N., "Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome", Osteoporos Int, 18(10), pp.1363~1370 (2007)
  14. Ikeda, F., "Activation of NFAT signal in vivo leads to osteopenia associated with increased osteoclastogenesis and bone-resorbing activity", J Immunol, 177(4), pp.2384~2390 (2006)
  15. Hayman, A.R, "Tartrate-resistant acid phosphatase (TRAP) and the osteoclast", immune cell dichotomy, 2008, pp.41(3), 218~223
  16. Yagi M, "DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells", J Exp Med, 202(3), pp.345~351 (2005)
  17. Kim,K..Kim,J.,Lee,J.Kim K,Lee S and Kim N, "MafB negatively regulates RANKL-mediated osteoclast differentiation", BLOOD, 109(8), pp.3253~3259 (2007), AMER SOC HEMATOLOGY
  18. Wagner, E.F, "Fos", AP-1 proteins in bone and the immune system, 2005, pp.208, 126~140
  19. Matsubara, T, "Critical role of cortactin in actin ring formation and osteoclastic bone resorption", J Bone Miner Metab, 24(5), pp.368~372 (2006)

관련 논문AI추천

파골세포의 분화와 뼈 흡수에 천남성의 억제 효과김하영, 박기인, 이명수, 이창훈한의병리학회 · 동의생리병리학회지2011 · 제25권 제1호적복령 추출물이 파골세포의 분화와 골흡수 억제에 미치는 효과곽한복, 김정중, 김주영, 김진숙, 문서영, 오재민, 이명수, 이승화, 이창훈, 조해중, 최민규대한골다공증학회 · OSTEOPOROSIS2012 · 제10권 제3호백작약 에탄올 추출물의 파골세포 분화 및 생성 억제 작용고원민, 구동륜, 김윤철, 박근하, 박보라, 이승훈한의병리학회 · 동의생리병리학회지2015 · 제29권 제1호白何首烏 물 추출물의 파골세포 분화에 미치는 영향문서영, 안용환, 오재민, 이명수, 전병훈, 정종혁, 채수욱, 최민규한의병리학회 · 동의생리병리학회지2012 · 제26권 제2호골쇄보가 RANKL에 의해 유도되는 파골세포의 분화에 미치는 영향곽성철, 곽한복, 김정중, 문서영, 오재민, 장성조, 전병훈, 최민규한의병리학회 · 동의생리병리학회지2012 · 제26권 제4호Effect of Cornus Officinalis on Receptor Activator of Nuclear Factor-kappaB Ligand (RANKL)-induced Osteoclast Differentiation곽한복, 김윤경, 김정영, 김정중, 오재민, 최민규대한골대사학회 · 대한골대사학회지2012 · 제19권 제2호

이 간행물의 다른 논문 (13건)

甘松香 물추출물이 U937 백혈병 세포의 분화유도에 미치는 영향전병훈, 전병제, 김진국, 양현모, 주성민pp. 29-36황금이 LPS로 유발된 급성 폐 손상에 미치는 영향박미연, 최해윤, 김종대, 신호필pp. 55-64파골세포의 분화와 뼈 흡수에 천남성의 억제 효과이창훈, 이명수, 박기인, 김하영pp. 65-70大黃이 흰쥐의 위점막 손상에 미치는 영향김범회pp. 71-77白蔘과 紅蔘이 포함된 理中湯의 마우스 대식세포 내 hydrogen peroxide 생성에 미치는 영향박완수pp. 78-83
원문 보기